drugset / Trial / NCT02177773

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

NCT02177773

NaSingle-groupOpen-labelDiagnostic

Summary

This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to somatostatin receptor positive tumors and can be seen using a PET scan. A PET scan uses a special camera to detect energy given off from gallium Ga 68-DOTA-TOC, to make detailed pictures of areas where material accumulates in the body. Diagnostic procedures, such as gallium Ga 68-DOTA-TOC PET/CT or PET/MRI, may help find and diagnose somatostatin receptor positive tumors and help plan the best treatment.

Timeline

Start
2014-06-23
Primary completion
2017-08-07
Completion
2017-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATOC Peptide Intravenous